Effects of long-term low-dose mifepristone on reproductive function in women

被引:58
作者
Croxatto, HB
Kovács, L
Massai, R
Resch, BA
Fuentealba, B
Salvatierra, AM
Croxatto, HD
Zalányi, S
Viski, S
Krenacs, L
机构
[1] Inst Chileno Med Reprod, Santiago, Chile
[2] Albert Szent Gyorgyi Med Univ, Dept Obstet & Gynaecol, H-6701 Szeged, Hungary
[3] Albert Szent Gyorgyi Med Univ, Dept Pathol, H-6701 Szeged, Hungary
关键词
antiprogestin; endometrial contraception; mifepristone; ovarian cycle; women;
D O I
10.1093/humrep/13.4.793
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were; observed in 25 and 34% respectively of the monophasic cycles, Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding, However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.
引用
收藏
页码:793 / 798
页数:6
相关论文
共 16 条
[1]   DELAYED ENDOMETRIAL MATURATION INDUCED BY DAILY ADMINISTRATION OF THE ANTIPROGESTIN RU-486 - A POTENTIAL NEW CONTRACEPTIVE STRATEGY [J].
BATISTA, MC ;
CARTLEDGE, TP ;
ZELLMER, AW ;
MERINO, MJ ;
AXIOTIS, C ;
LORIAUX, DL ;
NIEMAN, LK .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (01) :60-65
[2]  
Cameron ST, 1996, HUM REPROD, V11, P2518
[3]   EFFECTS OF CONTINUOUS TREATMENT WITH LOW-DOSE MIFEPRISTONE THROUGHOUT ONE MENSTRUAL-CYCLE [J].
CROXATTO, HB ;
SALVATIERRA, AM ;
CROXATTO, HD ;
FUENTEALBA, B .
HUMAN REPRODUCTION, 1993, 8 (02) :201-207
[4]  
Deraedt R., 1985, ANTIPROGESTIN STEROI, DOI 10.1007/978-1-4684-1242-0_9
[5]  
GEMZELLDANIELSS.K, 1997, HUM REPROD, V12, P124
[6]   Effect of low weekly doses of mifepristone on ovarian function and endometrial development [J].
GemzellDanielsson, K ;
Westlund, P ;
Johannisson, E ;
Swahn, ML ;
Bygdeman, M ;
Seppala, M .
HUMAN REPRODUCTION, 1996, 11 (02) :256-264
[7]   EARLY LUTEAL-PHASE TREATMENT WITH MIFEPRISTONE (RU-486) FOR FERTILITY REGULATION [J].
GEMZELLDANIELSSON, K ;
SWAHN, ML ;
SVALANDER, P ;
BYGDEMAN, M .
HUMAN REPRODUCTION, 1993, 8 (06) :870-873
[8]   ENDOMETRIAL AND PITUITARY RESPONSES TO THE STEROIDAL ANTIPROGESTIN RU-486 IN POSTMENOPAUSAL WOMEN [J].
GRAVANIS, A ;
SCHAISON, G ;
GEORGE, M ;
DEBRUX, J ;
SATYASWAROOP, PG ;
BAULIEU, EE ;
ROBEL, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (01) :156-163
[9]  
Hosmer D., 1989, Applied Logistic Regression, V1st, DOI DOI 10.1097/00019514-200604000-00003
[10]   Pharmacokinetics of mifepristone after low oral doses [J].
Kekkonen, R ;
Heikinheimo, O ;
Mandelin, E ;
Lahteenmaki, P .
CONTRACEPTION, 1996, 54 (04) :229-234